Treatment Innovations

Redefining the Frontier: Navigating Evidence Generation for Ultra-Rare Diseases redefining-the-frontier-navigating-evidence-generation-for-ultra-rare-diseases

Redefining the Frontier: Navigating Evidence Generation for Ultra-Rare Diseases

Layla Zulfa May 9, 2026

The development of therapies for ultra-rare diseases—conditions affecting fewer than 1,000, and sometimes fewer than 10, individuals—represents...

Glucotrack Advances Next-Generation Diabetes Care with IDE Submission for Implantable Glucose Monitor glucotrack-advances-next-generation-diabetes-care-with-ide-submission-for-implantable-glucose-monitor

Glucotrack Advances Next-Generation Diabetes Care with IDE Submission for Implantable Glucose Monitor

Muslim May 9, 2026

In a pivotal step for the diabetes technology landscape, medical device innovator Glucotrack has officially submitted an...

Sarepta Therapeutics at a Crossroads: Beyond Elevidys and the Pivot to RNA Innovation sarepta-therapeutics-at-a-crossroads-beyond-elevidys-and-the-pivot-to-rna-innovation

Sarepta Therapeutics at a Crossroads: Beyond Elevidys and the Pivot to RNA Innovation

Muslim May 9, 2026

By Industry Analysis Desk Published May 7, 2026 In the high-stakes world of biotechnology, few companies have...

A Paradigm Shift in Neuro-Oncology: UCLA Researchers Advance Tailored EGFR-Targeted Therapy for Glioblastoma a-paradigm-shift-in-neuro-oncology-ucla-researchers-advance-tailored-egfr-targeted-therapy-for-glioblastoma

A Paradigm Shift in Neuro-Oncology: UCLA Researchers Advance Tailored EGFR-Targeted Therapy for Glioblastoma

Laily UPN May 9, 2026

In the relentless battle against glioblastoma—the most aggressive and lethal form of primary brain cancer—a team of...

Advancing Urological Diagnostics: Bright Uro’s Glean System Receives Pivotal FDA Clearance advancing-urological-diagnostics-bright-uros-glean-system-receives-pivotal-fda-clearance

Advancing Urological Diagnostics: Bright Uro’s Glean System Receives Pivotal FDA Clearance

Lina Hope May 9, 2026

The landscape of urological diagnostics is undergoing a significant transformation. Bright Uro, a California-based medical technology innovator,...

Pharma’s Aggressive 2026: A Multi-Billion Dollar M&A Resurgence pharmas-aggressive-2026-a-multi-billion-dollar-ma-resurgence

Pharma’s Aggressive 2026: A Multi-Billion Dollar M&A Resurgence

Evan Lee Salim May 9, 2026

The global pharmaceutical landscape is currently undergoing a transformative shift, marked by an aggressive return to dealmaking...

A Decade of Precision: How Functional NAMs are Transforming Cardiac Safety Assessment a-decade-of-precision-how-functional-nams-are-transforming-cardiac-safety-assessment

A Decade of Precision: How Functional NAMs are Transforming Cardiac Safety Assessment

Azzam Bilal Chamdy May 8, 2026

The landscape of pharmaceutical safety assessment is undergoing a profound metamorphosis. For decades, the industry has relied...

Rivanna’s Accuro XV Secures FDA Clearance: A New Frontier in Point-of-Care Musculoskeletal Imaging rivannas-accuro-xv-secures-fda-clearance-a-new-frontier-in-point-of-care-musculoskeletal-imaging

Rivanna’s Accuro XV Secures FDA Clearance: A New Frontier in Point-of-Care Musculoskeletal Imaging

Ammar Sabilarrohman May 8, 2026

In a major milestone for point-of-care diagnostics, Virginia-based medical technology innovator Rivanna has received US Food and...

Strategic Expansion: Angelini Pharma to Acquire Catalyst Pharmaceuticals in $4.1 Billion Neuroscience Powerplay strategic-expansion-angelini-pharma-to-acquire-catalyst-pharmaceuticals-in-4-1-billion-neuroscience-powerplay

Strategic Expansion: Angelini Pharma to Acquire Catalyst Pharmaceuticals in $4.1 Billion Neuroscience Powerplay

Nila Kartika Wati September 9, 2025

By Gwendolyn Wu Published May 7, 2026 In a move that signals a significant shift in the...

From Spreadsheets to Strategy: How AI is Overhauling the $5.9 Million Clinical Data Bottleneck from-spreadsheets-to-strategy-how-ai-is-overhauling-the-5-9-million-clinical-data-bottleneck

From Spreadsheets to Strategy: How AI is Overhauling the $5.9 Million Clinical Data Bottleneck

Pevita Pearce August 4, 2025

In the high-stakes world of pharmaceutical development, where a single Phase 3 clinical trial can represent billions...

Redefining the Frontier: Navigating Evidence Generation for Ultra-Rare Diseases

Glucotrack Advances Next-Generation Diabetes Care with IDE Submission for Implantable Glucose Monitor

Sarepta Therapeutics at a Crossroads: Beyond Elevidys and the Pivot to RNA Innovation

A Paradigm Shift in Neuro-Oncology: UCLA Researchers Advance Tailored EGFR-Targeted Therapy for Glioblastoma

Advancing Urological Diagnostics: Bright Uro’s Glean System Receives Pivotal FDA Clearance

Pharma’s Aggressive 2026: A Multi-Billion Dollar M&A Resurgence

A Decade of Precision: How Functional NAMs are Transforming Cardiac Safety Assessment

Rivanna’s Accuro XV Secures FDA Clearance: A New Frontier in Point-of-Care Musculoskeletal Imaging

Strategic Expansion: Angelini Pharma to Acquire Catalyst Pharmaceuticals in $4.1 Billion Neuroscience Powerplay

From Spreadsheets to Strategy: How AI is Overhauling the $5.9 Million Clinical Data Bottleneck

You may have missed

The Coming Patent Cliff: Can Biosimilars Break the Stranglehold on Keytruda?

DEA Escalates Regulatory Crackdown on Synthetic Kratom Derivatives: A New Frontier in Controlled Substance Enforcement

Ibuprofen’s Hidden Power: Could Your Everyday Painkiller Also Fight Cancer?

AstraZeneca Halts Promising Kidney Transplant Trial for Ultomiris Amidst Strategic Pivot